It’s no exaggeration to say the development of Micronoma’s Oncobiota™ microbiome-driven liquid-biopsy technology to detect cancer at an early stage would not be possible without extensive expertise and use of machine learning (ML) tools. Micronoma’s proprietary...
Chuck Rosales joined Micronoma in July 2021 as the quality manager, responsible for implementing and maintaining all compliance and quality procedures to ensure that patient testing is performed with the highest standards. Though born in Kansas, he has lived in San...
When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...
Todd Czerwinski will oversee the development and execution of market access, strategic partnerships and sales as the company rolls out its groundbreaking early cancer diagnosis platform SAN DIEGO, May 24, 2022 — Micronoma, the first cancer detection biotech company...
Inclusion of microbiome supports Micronoma’s efforts to improve cancer detection The “hallmarks of cancer” have captured the core features of cancer biology and served as a guide for future research since their original publication in Cell in 2000. Since then, the...
